Article: An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleAn H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
AuthorsZhao, G1
Sun, S1
Du, L4
Xiao, W1
Ru, Z1 3
Kou, Z1
Guo, Y1
Yu, H1
Jiang, S4
Lone, Y3
Zheng, BJ2
Zhou, Y1
Issue Date2010
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
CitationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-151
AbstractBackground. A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results. Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. Conclusions. Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus. © 2010 Zhao et al; licensee BioMed Central Ltd.
ISSN1743-422X
2011 Impact Factor: 2.343
2011 SCImago Journal Rankings: 0.216
DOIhttp://dx.doi.org/10.1186/1743-422X-7-151
ISI Accession Number IDWOS:000282601300001
Funding AgencyGrant Number
Natural Science Foundation of China30901371
Mega-projects of Science Research for the 11th Five-Year Plan2009ZX10004-401
National Basic Research Program of China (973 Program)2005CB523001
National Science and Technology Infrastructure Program2006BA06A15
Funding Information:

This study was supported by Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), National Basic Research Program of China (973 Program, 2005CB523001), and National Science and Technology Infrastructure Program (2006BA06A15).

PubMed Central IDPMC2912260
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorZhao, G
dc.contributor.authorSun, S
dc.contributor.authorDu, L
dc.contributor.authorXiao, W
dc.contributor.authorRu, Z
dc.contributor.authorKou, Z
dc.contributor.authorGuo, Y
dc.contributor.authorYu, H
dc.contributor.authorJiang, S
dc.contributor.authorLone, Y
dc.contributor.authorZheng, BJ
dc.contributor.authorZhou, Y
dc.date.accessioned2011-07-27T01:31:05Z
dc.date.available2011-07-27T01:31:05Z
dc.date.issued2010
dc.description.abstractBackground. A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results. Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. Conclusions. Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus. © 2010 Zhao et al; licensee BioMed Central Ltd.
dc.description.naturepublished_or_final_version
dc.identifier.citationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-151
dc.identifier.citeulike7493888
dc.identifier.doihttp://dx.doi.org/10.1186/1743-422X-7-151
dc.identifier.hkuros188635
dc.identifier.isiWOS:000282601300001
Funding AgencyGrant Number
Natural Science Foundation of China30901371
Mega-projects of Science Research for the 11th Five-Year Plan2009ZX10004-401
National Basic Research Program of China (973 Program)2005CB523001
National Science and Technology Infrastructure Program2006BA06A15
Funding Information:

This study was supported by Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), National Basic Research Program of China (973 Program, 2005CB523001), and National Science and Technology Infrastructure Program (2006BA06A15).

dc.identifier.issn1743-422X
2011 Impact Factor: 2.343
2011 SCImago Journal Rankings: 0.216
dc.identifier.pmcidPMC2912260
dc.identifier.pmid20624292
dc.identifier.scopuseid_2-s2.0-77954409486
dc.identifier.urihttp://hdl.handle.net/10722/135277
dc.identifier.volume7
dc.languageeng
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVirology Journal
dc.relation.referencesReferences in Scopus
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.rightsVirology Journal. Copyright © BioMed Central Ltd.
dc.subject.meshCross Protection
dc.subject.meshDisease Outbreaks
dc.subject.meshInfluenza Vaccines - administration and dosage - immunology
dc.subject.meshInfluenza, Human - epidemiology - immunology - prevention and control - virology
dc.subject.meshViral Matrix Proteins - administration and dosage - chemistry - immunology
dc.titleAn H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
dc.typeArticle
Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. Universite Paris-Sud XI
  4. New York Blood Center